Collaborating with Visionary
Biopharma Partners.
We structure regional co-development agreements, foundation partnerships, and institutional investment rounds to accelerate global commercial delivery of Zegen-X5 across an $18B+ advanced wound-care market.
Strategic Collaboration Opportunities
Tailored transaction structures designed for regional biopharmaceutical commercial leaders, government agencies, and philanthropic foundations.
Regional Pharma Licensing
Territory-exclusive commercial and co-development rights for Phase II/III clinical expansion and hospital/outpatient marketing across North America, Europe, Japan, and Asia-Pacific.
Defense & Emergency Triage
Government and defense medical agreements (BARDA, DoD, NATO allies) for ambient-stable, touchless burn and blast trauma treatments deployable without refrigeration in field triage.
Global Health Philanthropy
Philanthropic foundation grant funding (e.g. Richard King Mellon Foundation) to pilot decentralized point-of-care wound management in underserved regions facing high diabetic amputation mortality.
Request Institutional Due Diligence Access
Accredited institutional investors, venture capital funds, and biopharmaceutical BD teams can request access to our confidential data room containing complete preclinical study packages, non-GLP tox reports, and patent filings.